MONOCLONAL ANTIBODY CD44 FOR TREATMENT OF B-CELLULAR CHRONIC LYMPHOCYTAR LEUKEMIA AND OTHER HEMATOLOGICAL MALIGNANT DISEASES

摘要

1. An isolated antibody or antibody fragment that specifically binds CD44.2. An antibody or antibody fragment according to claim 1, wherein the antibody fragment is selected from the group consisting of a Fab fragment, F (ab) 2 fragment, FV fragment, single chain FV fragment (scFV), dsFV fragment, CH fragment and dimeric scFV. 3. An antibody or antibody fragment according to claim 1, characterized in that the antibody or antibody fragment is humanized. An antibody or antibody fragment according to claim 1, characterized in that the antibody or antibody fragment specifically binds CD44 expressed on CLL cells. A pharmaceutical composition comprising an antibody or antibody fragment according to claim 1 and a pharmaceutically acceptable carrier. An isolated nucleic acid molecule that encodes the antibody of claim 1.7. An expression vector that contains a nucleic acid molecule according to claim 6.8. A method for producing an antibody or antibody fragment according to claim 1, wherein the method comprises: i) transforming the host cell with an expression construct comprising the nucleic acid molecule encoding the antibody or antibody fragment according to claim 1; and ii) culturing the host cell under conditions suitable for producing a conjugate, thereby producing a protein conjugate. A method for detecting a CD44 protein in a sample, the method comprising: (a) contacting the sample with a detectably labeled antibody or antibody fragment according to claim 1; and (b) determining the immunoreactivity between the detectably labeled peptide and CD44 in the sample. The method of claim 9, further comprising (c) determining whether the amount of CD44 protein in the subject is increased or decreased compared to the control level of CD44.11.